5757-66-4

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-2,6-dimethylbenzenecarbonitrile is used as a precursor in the synthesis of various pharmaceuticals for its ability to be chemically modified to create a range of medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-2,6-dimethylbenzenecarbonitrile is utilized as a starting material for the development of new agrochemicals, potentially leading to more effective and targeted pest control solutions.
Used in Dye Industry:
4-bromo-2,6-dimethylbenzenecarbonitrile is used as an intermediate in the production of dyes, contributing to the creation of a variety of colorants for different applications.
Used in Specialty Chemicals Production:
4-bromo-2,6-dimethylbenzenecarbonitrile is employed as an intermediate in the manufacturing process of specialty chemicals, where its unique structure allows for the development of high-value products.
Used in Organic Synthesis and Research:
As a versatile building block in organic chemistry, 4-bromo-2,6-dimethylbenzenecarbonitrile is used in research and development for creating new organic compounds and exploring novel synthetic pathways.

InChI:InChI=1/C9H8BrN/c1-6-3-8(10)4-7(2)9(6)5-11/h3-4H,1-2H3

Upstream product

• 88679-80-5 C₈H₈BrN₂⁽¹⁺⁾*Cl^(1-) 
• 143-33-9 sodium cyanide 
• 24596-19-8 4-bromo-2,6-dimethylphenylamine 
• 544-92-3 copper(I) cyanide 
• 151-50-8 potassium cyanide 
• 773837-37-9 sodium cyanide 
• 55305-43-6 N-cyano-N-phenyl-p-toluenesulfonamide 
• 87-62-7 2,6-dimethylaniline 

Downstream Products

• 74346-19-3 4-bromo-2,6-dimethylbenzoic acid 
• 5769-33-5 2,6-dimethyl-4-bromobenzaldehyde 
• 132949-41-8 4-Bromo-2,6-dimethylbenzamide 
• 289617-96-5 4-bromo-2,6-bis(bromomethyl)benzonitrile 
• 300539-43-9 4-bromo-2,6-bis-(2-methoxy-ethoxymethyl)-benzonitrile 
• 300539-77-9 2,6-bis-(2-methoxy-ethoxymethyl)-4-trimethylsilyl-benzonitrile 
• 300539-44-0 4-bromo-2,6-bis-(2,5,8-trioxanonyl)-benzonitrile 
• 300539-78-0 4-trimethylsilyl-2,6-bis-(2,5,8-trioxanonyl)-benzonitrile 
• 300539-45-1 4-bromo-2,6-bis-(2,5,8,11-tetraoxadodecyl)-benzonitrile 
• 300539-75-7 4,4'-dicyano-3,3',5,5'-tetrakis-(2-methoxy-ethoxymethyl)tolan 
• 300539-76-8 4,4'-dicyano-3,3',5,5'-tetrakis-(2,5,8-trioxanonyl)tolan 
• 300539-72-4 1,3,5-tris([4-cyano-3,5-bis(2-methoxy-ethoxymethyl)phenyl]-ethynyl)benzene 
• 300539-73-5 1,3,5-tris([4-cyano-3,5-bis(2,5,8-trioxanonyl)phenyl]-ethynyl)benzene 
• 90924-01-9 4-cyano-3,5-dimethylbenzoic acid 

Relevant academic research and scientific papers

The application of NCTS (N-cyano-N-phenyl-p-toluenesulfonamide) in palladium-catalyzed cyanation of arenediazonium tetrafluoroborates and aryl halides

Using NCTS (N-cyano-N-phenyl-p-toluenesulfonamide) as an electrophilic cyanation reagent, palladium-catalyzed cyanation of arenediazonium tetrafluoroborates and aryl halides was achieved under mild conditions. The method allowed the effective synthesis of various aryl nitriles in suitable yields via a coupling reaction.

Vectorial electron transfer in donor-photosensitizer-acceptor triads based on novel bis-tridentate ruthenium polypyridyl complexes

The first examples of rodlike donor-photosensitizer-acceptor arrays based on bis-2,6-di(quinolin-8-yl)pyridine RuII complexes 1a and 3a for photoinduced electron transfer have been synthesized and investigated. The complexes are synthesized in a convergent manner and are isolated as linear, single isomers. Time-resolved absorption spectroscopy reveals long-lived, photoinduced charge-separated states (τCSS (1a)=140 ns, τCSS (3a)=200 ns) formed by stepwise electron transfer. The overall yields of charge separation (≥50% for complex 1a and ≥95% for complex 3a) are unprecedented for bis-tridentate RuII polypyridyl complexes. This is attributed to the long-lived excited state of the [Ru(dqp)2]2+ complex combined with fast electron transfer from the donor moiety following the initial charge separation. The rodlike arrangement of donor and acceptor gives controlled, vectorial electron transfer, free from the complications of stereoisomeric diversity. Thus, such arrays provide an excellent system for the study of photoinduced electron transfer and, ultimately, the harvesting of solar energy.

NOVEL ANTI-INFLAMMATORY AGENTS

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Vasopressin (AVP) is a hormone that stimulates an increase in water permeability through activation of V2 receptors in the kidney. The analogue of AVP, desmopressin, has proven an effective drug for diseases where a reduction of urine output is desired. However, its peptidic nature limits its bioavailability. We report herein the discovery of potent, nonpeptidic, benzylurea derived agonists of the vasopressin V2 receptor. We describe substitutions on the benzyl group to give improvements in potency and subsequent modifications to the urea end group to provide improvements in solubility and increased oral efficacy in a rat model of diuresis. The lead compound 20e (VA106483) is reported for the first time and has been selected for clinical development.

HYDRAZIDES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 681

The present invention is directed to compounds of Formula I: wherein A and R1 to R8 are as defined in the specification.

INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS

Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.

ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.

Piperazines as oxytocin agonists

Disclosed are novel compounds according to general formula I, which have shown OT agonist activity.

benzamide derivatives as oxytocin agonists and vasopressin antagonists

Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.